Antibody response to the non-adjuvanted and adjuvanted influenza A H1N1/09 monovalent vaccines in renal transplant recipients

Transplant Infectious Disease

Volumn 14, Issue 6, 2012, Pages 564-574

  Salles, M J C ^a   Sens, Y A S ^b   Malafronte, P ^b   Souza, J F ^b   Vilas Boas, L S ^c   Machado, C M ^c  

^a Assistant Prof Internal Medicine Dept Santa Casa School of Medicine and Hospitals of São Paulo   (Brazil)

^b Santa Casa of Sao Paulo School of Medicine   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adjuvanted and non adjuvanted vaccine; Antibody response; Influenza A H1N1; Renal transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN A; INFLUENZA VACCINE; MYCOPHENOLIC ACID; PREDNISONE; RAPAMYCIN; TACROLIMUS;

2009 H1N1 INFLUENZA; ADULT; AGE DISTRIBUTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG SAFETY; ERYTHEMA; FEMALE; GRAFT RECIPIENT; HEMAGGLUTINATION INHIBITION TEST; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROCONVERSION; SINGLE DRUG DOSE; SWELLING; VACCINATION;

ADJUVANTS, ANESTHESIA; ANTIBODIES, VIRAL; BRAZIL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; KIDNEY TRANSPLANTATION; PANDEMICS;

EID: 84871022629     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2012.00769.x     Document Type: Article

References (40)

1. Vilchez RA, Fung J, Kusne S. The pathogenesis and management of influenza virus infection in organ transplant recipients. Transpl Infect Dis 2002; 4 (4): 177-182.
2. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009; 9 (8): 493-504.
3. Danzinger-Isakov L, Kumar D, and the AST Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009; 9 (Suppl 4): S258-S262.
4. Harris K, Baggs J, Davis RL, et al. Influenza vaccination coverage among adult solid organ transplant recipients at three health maintenance organizations, 1995-2005. Vaccine 2009; 27 (17): 2335-2341.
5. Birdwell KA, Ikizler MR, Sannella EC, et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. Am J Kidney Dis 2009; 54 (1): 112-121.
6. Sanchez-Fructuoso AI, Prats D, Naranjo P, et al. Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: mycophenolate versus azathioprine. Transplantation 2000; 69 (3): 436-469.
7. Scharpé J, Evenepoel P, Maes B, et al. Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant 2008; 8 (2): 332-337.
8. Salles MJC, Sens YAS, Boas LSV, Machado CM. Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugs. Clin Transplant 2010; 24 (1): E17-E23.
9. Ison MG. Influenza, including the novel H1N1, in organ transplant patients. Curr Opin Infect Dis 2010; 23 (4): 365-373.
10. Jamieson DJ, Honein MA, Rasmussen SA, et al. Novel Influenza A (H1N1) Pregnancy Working Group. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 2009; 374 (9688): 451-458.
11. Lister P, Reynolds F, Parslow R, et al. Swine-origin influenza virus H1N1, seasonal influenza virus, and critical illness in children. Lancet 2009; 374 (9690): 605-607.
12. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza; Bautista E, Chotpitayasunondh T, Gao Z, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362 (18): 1708-1719. Erratum 2010; 362 (21): 2039.
13. Kumar D, Michaels MG, Morris MI, et al. On behalf of the American Society of Transplantation H1N1 Collaborative Study Group. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010; 10 (8): 521-526.
14. Kumar D, Morris MI, Kotton CN, et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant 2010; 10 (1): 18-25.
15. Strategic Advisory Group of Experts on Immunization-report of the extraordinary meeting on the influenza A (H1N1) 009 pandemic, 7 July 2009. Wkly Epidemiol Rec 2009; 84 (30): 301-304.
16. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361 (20): 1945-1952.
17. Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361 (25): 2424-2435.
18. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361 (25): 2405-2413.
19. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomized trial. Vaccine 2010; 28 (7): 1740-1745.
20. Liang XF, Wang HQ, Wang JZ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomized, placebo-controlled trial. Lancet 2010; 375 (9708): 56-66.
21. Zhu FC, Wang H, Fang HH, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 361 (25): 2414-2423.
22. Vajo Z, Tamas F, Sinka L, Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010; 375 (9708): 49-55.
23. Manuel O, Pascual M, Hoschler K, et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011; 52 (2): 248-256.
24. Bickel M, Hentig N, Wieters I, et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis 2011; 52 (1): 122-127.
25. Launay O, Desaint C, Durier C, Loulergue P, et al. Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis 2011; 204 (1): 124-134.
26. Dikow R, Eckerle I, Ksoll-Rudek D, et al. Immunogenicity and efficacy in hemodialysis patients of an AS03A-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial. Am J Kidney Dis 2011; 57 (5): 716-723.
27. Gueller S, Allwinn R, Mousset S, et al. Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17 (10): 1546-1550.
28. Felldin M, Studahl M, Svennerholm B, Friman V. The antibody response to pandemic H1N1 2009 influenza vaccine in adult organ transplant patients. Transpl Int 2012; 25 (2): 166-171. Epub 26 November 2011.
29. Broeders NE, Hombrouck A, Lemy A, et al. Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. Clin J Am Soc Nephrol 2011; 6 (11): 2573-2578.
30. Meyer S, Adam M, Schweige B, et al. Antibody response after a single dose of an AS03- adjuvanted split-virion influenza A (H1N1) vaccine in heart transplant recipients. Transplantation 2011; 91 (9): 1031-1035.
31. ®) in renal transplant recipients. Nephrol Dial Transplant 2012; 27 (1): 423-428. Epub 25 May 2011.
32. Cordero E, Perez-Ordoñez A, Aydillo TA, et al. Therapy with m-TOR inhibitors decreases the response to the pandemic influenza A H1N1 vaccine in solid organ transplant recipients. Am J Transplant 2011; 11: 2205-2213.
33. Danziger-Isakov L, Cherkassky L, Siegel H, et al. Effects of influenza immunization on humoral and cellular alloreactivity in humans. Transplantation 2010; 89 (7): 838-844.
34. Katerinis I, Hadaya R, Duquesnoy R, et al. De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant 2011; 11 (8): 1727-1733.
35. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010; 375 (9708): 41-48.
36. Kendal AP, Pereira MS, Skehel JJ, eds. Concepts and Procedures for Laboratory-Based Influenza Surveillance. Atlanta, GA: US Department of Health and Human Services, CDC, 1982.
37. WHO. World Health Organization Manual on Animal Influenza Diagnosis and Surveillance 2009. Accessed 15 March 2010. http://www.who.int/vaccine_research/diseases/influenza/WHO_manual_on_animal-diagnosis_and_surveillance_02_5.pdf.
38. Beyer WE, Palache AM, Luchters G, Nauta J, Osterhaus ADME. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res 2004; 103 (1-2): 125-132.
39. European Committee for Proprietary Medicinal Products. Guideline on Dossier Structure and Content for Pandemic Influenza Vaccine Marketing Authorization Application (CPMP/VEG/4717/03). London: European Agency for the Evaluation of Medicinal Products, 2004.
40. European Committee for Proprietary Medicinal Products. Guideline on Influenza Vaccine Prepared from Viruses with the Potential to Cause a Pandemic and Intended for Use Outside of the Core Dossier Context (EMEA/CHMP/VWP/263499/2006). London: European Agency for the Evaluation of Medicinal Products, 2007.